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Abstract
Purpose Sacubitril/valsartan (LCZ696) is a first-in-class an-
giotensin receptor neprilysin inhibitor (ARNI) indicated to
reduce the risk of cardiovascular death and hospitalization
for heart failure in patients with chronic heart failure
(NYHA class II–IV) and reduced ejection fraction. This study
was aimed to evaluate the effect of single oral therapeutic
(400 mg) and supratherapeutic (1200 mg) doses of LCZ696
on cardiac repolarization.
Method This randomized double-blind crossover study in
healthy male subjects compared the effect of therapeutic and
supratherapeutic doses of LCZ696 with placebo and
moxifloxacin 400 mg (open-label treatment) as positive con-
trol. The primary assessment was mean baseline- and placebo-
corrected QTcF (ΔΔQTcF; Fridericia correction). Additional
assessments included the ΔΔQTcB (Bazett’s correction), PR
interval, QRS duration, heart rate (HR), LCZ696
pharmacokinetics, pharmacokinetic/pharmacodynamic rela-
tionships, and safety.
Results Of the 84 subjects enrolled, 81 completed the study.
The maximum upper bound of the two-sided 90% confidence
interval for ΔΔQTcF for LCZ696 400 mg and 1200 mg were
<10 ms, and assay sensitivity was confirmed with
moxifloxacin. No relevant treatment-emergent changes were
observed in any of the ECG-derived parameters with LCZ696
or placebo, and the incidence of adverse events was compa-
rable among the treatment groups.
Conclusion Single therapeutic and supratherapeutic doses of
LCZ696 did not affect cardiac repolarization as defined by the
E14 ICH guidelines.
Keywords Angiotensin receptor neprilysin inhibitor .Cardiac
repolarization . Heart failure . LCZ696 . QT prolongation .
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Introduction
Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin
receptor neprilysin inhibitor (ARNI) indicated to reduce the
risk of cardiovascular death and hospitalization for heart fail-
ure in patients with chronic heart failure (NYHA class II–IV)
and reduced ejection fraction (HFrEF) [1, 2]. Following oral
administration, LCZ696 provides systemic exposure to the
pro-drug sacubitril (also known as AHU377, which is further
metabolized to the active neprilysin inhibitor LBQ657) and
valsartan [3]. The mechanism of the beneficial effects of
LCZ696 in HF are believed to be due to the enhancement of
protective endogenous neurohormonal systems, such as the
natriuretic peptide (NP) system, in the presence of simulta-
neous inhibition of the deleterious effects related to sustained
renin-angiotensin-aldosterone system (RAAS) activation.
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Drug-induced delayed cardiac repolarization, as reflected
by a prolongation of the rate-corrected QT interval (QTc) is
an important cardiac safety finding leading to the withdrawal
of numerous drugs from the market [4, 5]. Drugs that have
potential to block the rapid component of the delayed rectifier
potassium channel (IKR) coded by human Ether-à-go-go relat-
ed gene (hERG) can prolong QTc, whichmay lead to increased
susceptibility to cardiac arrhythmias, notably Torsades de
Pointes [4, 6, 7]. Therefore, rigorous characterization of novel
pharmaceutical agents for their potential to prolong the QTc
interval is warranted as part of their cardiac safety assessment.
Clinical and experimental evidence corroborate the benefi-
cial effects of chronic treatment with RAAS inhibitors on the
duration of QT interval in patients with hypertension and HF
[8]. While this may reflect the end result of several indirect
factors, the impact of RAAS inhibitors on the electrophysio-
logical mechanisms altered by angiotensin II might be a pos-
sible reason [9]. Angiotensin II probably prolongs the action
potential by inhibiting the rapidly activating components of
IKR [10]. The beneficial effect of valsartan in HF is clinically
evident, while sacubitril showed no relevant effect on the
hERG/IKR channel current even at the highest LCZ696 con-
centration tested (3000 μM; <50 % inhibition) in vitro (data
on file). Although in vitro ion-channel assessment of LBQ657
was not performed, QT prolongation was not documented
during systematic in vivo exposure in primates (LCZ696)
and dogs (sacubitril). This study therefore provided a dedicated
assessment of effects of single oral therapeutic (400 mg) and
supratherapeutic (1200 mg) doses of LCZ696 on cardiac re-
polarization to support the use in patients with HF.
Methods
Subjects
Healthy male subjects 18–45 years of age with a body weight
≥60 kg, a bodymass index (BMI) of 18–28 kg/m2, and normal
ECG, vital signs, and laboratory tests were enrolled in the
study. The key exclusion criteria were use of other investiga-
tional drugs within 30 days of enrollment or within five half-
lives of treatment, contraindications to the use of
moxifloxacin, a history of angioedema or drug/alcohol abuse,
or donation or loss of ≥400mL of blood within 8 weeks before
initial dosing. All subjects provided written informed consent
before starting any of the study-related procedures.
Study design
This was a single-center, randomized, positive- and placebo-
controlled, partially blinded, single-dose study with a 4×3
Williams crossover design with 12 treatment sequences
(Fig. 1). Following a screening period of up to 21 days,
eligible subjects entered the randomized double-blind treat-
ment periods consisting of four 48-h treatment periods sepa-
rated by washout periods of ≥4 days each. The final study
completion evaluation was performed 4–10 days after the last
treatment. Subjects were admitted at least 35 h before treat-
ment in each treatment period for baseline assessments includ-
ing 24-h ECG Holter recording and were permitted to leave
the center during the washout periods.
The subjects were randomized to one of the 12 treatment
sequences and received four treatments: single oral doses of
LCZ696 400 mg (therapeutic dose), LCZ696 1200 mg
(supratherapeutic dose), placebo, or moxifloxacin 400 mg.
Treatments with LCZ696 and placebo were blinded, whereas
moxifloxacin treatment was administered in an open-label
manner.
Food and beverages that could potentially impact the PK of
LCZ696 analytes or ECG measurements, such as citrus fruits,
grapefruit, and quinine (e.g., tonic water), were restricted
within 3 days before or during treatment periods, while alco-
hol and substances containing methylxanthines (e.g., caffeine,
cola, chocolate) were restricted 10 h before the start of the
continuous ECG measurement and during the clinic stay of
each treatment period.
The study protocol was approved by the Ethics Committee of
the study center. The study was designed and implemented in
accordance with the ICH Guidelines for Good Clinical Practice
E6 [11] and for Clinical Evaluation of QT/QTc Interval
Prolongation and Proarrhythmic Potential for Non-
Antiarrhythmic Drugs E14 [12], applicable local regulations,
and the ethical principles laid down in the Declaration of
Helsinki.
Pharmacodynamic assessments
The primary assessment was the mean baseline- and placebo-
corrected Fridericia-corrected QT (ΔΔQTcF). The secondary
assessments included the ΔΔQTcB (Bazett’s correction);
QTcF and QTcB assay sensitivity with moxifloxacin; propor-
tion of subjects with notable changes in corrected (QTcF and
QTcB) and uncorrected QT (defined as an increase of >30 or
>60 ms from baseline or a change to >450, >480, or >500 ms,
if the condition not existed at baseline); changes in PR inter-
val, QRS duration, and HR and the proportion of subjects with
notable changes from baseline in these parameters defined as
40>HR>100, PR>200, and QRS>110 ms in the presence
of 25 % change from pretreatment.
Continuous 24-hHolter ECGswere collected at baseline and
following drug administration in each treatment period. ECGs
were extracted from the Holter recordings at −1 h, −35min, and
−15 min for baseline, and at 0.5, 1, 2, 3, 4, 5, 8, 12, and 24 h
relative to the dosing time for post-dose assessment. ECGswere
analyzed in a blinded fashion in a central ECG laboratory
(iCardiac Technologies Inc., Rochester, NY, USA).
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Pharmacokinetic assessments
The pharmacokinetic (PK) parameters including peak plas-
ma drug concentration (Cmax), time to reach Cmax (Tmax),
area under the plasma concentration-time curve from 0 to
24 h post-dose (AUC0–24 h), and AUC up to the last mea-
surable concentration (AUClast) for sacubitril, LBQ657 and
valsartan were determined by noncompartmental methods
using WinNonlin Phoenix version 6.2 (Pharsight
Corporation, Mountain View, CA). The exposure-
response relationship for QTcF during LCZ696 treatment
was also assessed.
For the assessments of PK parameters, serial blood samples
were collected at predose and 0.5, 1, 2, 3, 4, 5, 8, 12, and 24 h
post-dose. Plasma was obtained at each time point and kept
frozen at ≤−15 °C until analysis. Quantification of sacubitril,
LBQ657, and valsartan in plasma was performed using a val-
idated liquid chromatography tandemmass spectroscopy (LC-
MS/MS) method [3]. The lower limits of quantification for
sacubitril, LBQ657, and valsartan were 1.00, 20.0, and
10.0 ng/mL, respectively.
Safety
Safety assessments included monitoring of all adverse events
(AEs) and serious AEs (SAEs) and their relationship to study
drugs. Vital signs and laboratory parameters were assessed at
regularly intervals, and additional safety ECGs were collected
and assessed to confirm subject safety during profile days.
Statistical analyses
A total of 84 subjects were planned to be randomized, assum-
ing a dropout rate of <10 %, to complete all the four treatment
periods of the study with at least 73 subjects. This would
provide ≥80 % power to obtain the upper bound of the two-
sided 90 % confidence interval (CI) for the comparison be-
tween LCZ696 and placebo below 10 ms, when the true dif-
ference between the two treatments was ≤4 ms, assuming a
standard deviation (SD) of change from baseline in QTc of
<11.5 ms.
The safety analysis set included all subjects receiving at
least one dose of the study drug. The PD analysis set included
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Treatment A: Single oral dose of 400 mg LCZ696 (1 x 400 mg tablet of LCZ696, plus 2 tablets of LCZ696 placebo)
Treatment B: Single oral dose of 1200 mg LCZ696 (3 x 400 mg tablets)
Treatment C: Single oral dose of 400 mg moxifloxacin (1 x 400 mg tablet of moxifloxacin)
Treatment D: Single oral dose of Placebo (3 x 0 mg tablets of placebo to match LCZ696 400 mg and 1200 mg)
BL, baseline
Fig. 1 Study design. Treatment A: Single oral dose of 400 mg LCZ696
(1 × 400 mg tablet of LCZ696, plus 2 tablets of LCZ696 placebo).
Treatment B: Single oral dose of 1200 mg LCZ696 (3 × 400 mg
tablets). Treatment C: Single oral dose of 400 mg moxifloxacin
(1 × 400 mg tablet of moxifloxacin). Treatment D: Single oral dose of
placebo (3 × 0 mg tablets of placebo to match LCZ696 400 mg and
1200 mg). BL, baseline
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all subjects with available PD data and no protocol deviations
that could have an impact on the PD data. The PK analysis set
included all subjects who received the study drug with at least
one available valid PK concentration without protocol devia-
tions that could have a relevant impact on the PK data.
For the assessment of the primary objective of the study,
the effects of single therapeutic and supratherapeutic doses of
LCZ696 on QTcF were compared with placebo using one-
sided t tests at the level of α=0.05 as per the requirements
of the ICH E14 guidelines [12]. The null hypothesis under
consideration was a change from baseline of placebo-
corrected QTc (ΔΔQTcF) >10 ms for at least one time point.
The lack of effect on QTc was considered to be established
upon the rejection of the null hypotheses, that is, if the upper
bound of all two-sided 90 % confidence intervals (or one-
sided 95 % upper bound) of ΔΔQTcF values at all the time
points were below 10 ms for LCZ696. Assay sensitivity was
concluded if the p value for at least one of the 4 comparisons at
the 1, 2, 3, and 4 h post-dose time points for moxifloxacin was
<0.0125 (Bonferroni correction).
Goodness-of-fit (best fit) graphs plotted to determine the
performance of the QT correction formulas, based on the
predose QTc-RR relationship (Supplementary Fig. S1), sug-
gest the Fridericia correction method (QTcF) as an appropriate
method as the Bazett correction method (QTcB) tended to
overcorrect at elevated HR. The PK-PD relationship was eval-
uated using a linear mixed-effect model.
Results
Subjects
Of the total 84 randomized subjects, 81 subjects completed the
study, with treatment noncompliance (one subject), difficulty
in swallowing the tablet (one subject), and withdrawal of con-
sent (one subject) being the reasons for discontinuations. The
mean age of the enrolled subjects was 32.8 years, all subjects
were men and majority of the subjects were Caucasians
(96.4 %), and mean (standard deviation) weight was
79 .0 (8 . 81 ) kg and a BMI o f 24 .5 (2 . 27 ) kg /m2
(Supplementary Table 1).
Pharmacodynamic assessments
The maximum mean ΔΔQTcF following the administration of
LCZ696 400 and 1200 mg was 2.9 and 3.6 ms, respectively,
observed at 1 h post-dose. The upper bound of the two-sided
90 % CI for all the ΔΔQTcF values remained below the 10 ms
threshold, with a maximum upper bound of 3.9 ms observed
at 2 h post-dose for LCZ696 400 mg, and 4.5 ms observed at
1 h post-dose for LCZ696 1200 mg (Fig. 2a). The baseline-
corrected QTcF (ΔQTcF) comparing all treatments with pla-
cebo is presented in Fig. 2b.
Following moxifloxacin administration, the maximum
mean ΔΔQTcF at 1 h post-dose was 11.9 ms, and the lower
bounds of the two-sided 90 % CIs for ΔΔQTcF was >0 ms at
all predefined post-dose time points, thereby confirming assay
sensitivity.
The mean changes in HR, PR interval, and QRS duration
from baseline by time and treatment are presented in
Supplement Fig. S2a, b, c. The maximal mean HR increase
from baseline was observed at 8 h after administration of
LCZ696 400 mg (10.5 bpm) and LCZ696 1200 mg
(11.4 bpm), and 12 h after administration of moxifloxacin
and placebo (6.9 and 6.3 bpm, respectively). There were no
treatment-related relevant changes in the mean PR interval
and QRS duration in any of the treatment groups.
Notable changes in ECG parameters
The proportions of subjects with treatment-emergent notable
changes in ECG parameters are presented in Supplementary
Table 2. No subject had treatment-emergent QTcF or uncor-
rected QT values of >480 ms or >500 ms, or an increase from
baseline by >60 ms. Treatment-emergent QTcF >450 ms oc-
curred only in one subject receiving moxifloxacin from 1 to
5 h post-dose, while an uncorrected QT >450 ms was ob-
served in 1 (1.2 %) subject receiving LCZ696 400 mg and
in 3 (3.7 %) subjects receiving moxifloxacin. An increase in
corrected QT from baseline by 30–60 ms was observed only
in the moxifloxacin group (2 [2.5 %]). No treatment-emergent
notable events related to changes in HR, PR interval, or QRS
duration were noted during LCZ696 treatment. In addition, no
changes in ECG related to repolarization or morphology were
noted during LCZ696 treatment.
Pharmacokinetic assessments
Pharmacokinetics of sacubitril, LBQ657, and valsartan fol-
lowing the administration of single oral doses of LCZ696
400 or 1200 mg under fasting condition are summarized in
Table 1. The mean plasma concentrations of sacubitril in-
creased rapidly with a median Tmax of 0.52 h for the 400 mg
dose and 1.05 h for the 1200 mg dose, followed by LBQ657,
with the corresponding Tmax values of 2.07 and 3.05 h, re-
spectively. The median Tmax for valsartan was 2.07 h for both
the LCZ696 400 mg and 1200 mg doses. The Cmax of
LBQ657 showed a dose proportional increase, while the
Cmax of sacubitril and valsartan showed less than proportional
increases between the doses. The arithmetic mean AUC0–24 h
and AUClast for sacubitril and LBQ657 increased approxi-
mately dose proportionally, but showed less than dose propor-
tional increase for valsartan.
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Pharmacokinetic and pharmacodynamics relationship
The estimated regression of plasma concentrations of LCZ696
analytes against ΔΔQTcF and the corresponding 90 % CI
(shaded area) are presented in Fig. 3. The upper bounds of
the model-predicted 90 % CI of the regression equation for
ΔΔQTcF were below 10 ms for all LCZ696 analytes, except
for sacubitril at concentrations >15000 ng/mL. The mean
Cmax of sacubitril following administration of a single thera-
peutic dose of 400 mg LCZ696 was 3210 ng/mL.
Safety
Of the 84 subjects enrolled and randomized, 29 subjects
(34.5 %) experienced at least one AE during the study
(Supplement Table 3). The overall incidence of AEs was com-
parable across the treatment groups (LCZ696 400 mg
[14.6 %], LCZ696 1200 mg [14.6 %], moxifloxacin 400 mg
[13.6 %], and placebo [12.2 %]). Headache, nasopharyngitis,
postural dizziness, and nausea were the most commonly re-
ported AEs. Majority of the AEs were of mild intensity and
resolved without any treatment. No deaths or SAEs were re-
ported during the study, and none of the AEs led to study
discontinuation of a subject. There were no clinically signifi-
cant changes in laboratory measurements, vital signs, and
safety ECGs.
Discussion
Patients with heart failure have an impaired repolarization
reserve [13], in addition to several other factors that may





























Fig. 2 QTcF following administration of LCZ696 400 mg, 1200 mg,
moxifloxacin 400 mg, and placebo by time point: a Baseline- and
placebo-corrected QTcF (ΔΔQTcF) and b baseline-corrected QTcF
(ΔQTcF). Data are mean± 95 % confidence intervals
Table 1 Pharmacokinetics of
LCZ696 analytes following
administration of therapeutic
(400 mg) and supratherapeutic
doses (1200 mg) of LCZ696
Parameter LCZ696 400 mg LCZ696 1200 mg
N Arithmetic mean (SD) CV% N Arithmetic mean (SD) CV%
Sacubitril
AUC0–24 h, h*ng/mL 81 4400 (1780) 40.4 82 13200 (4640) 35.3
AUClast, h*ng/mL 82 4390 (1760) 40.2 82 13100 (4640) 35.3
Cmax, ng/mL 82 3210 (1690) 52.6 82 7780 (3830) 49.2
Tmax, h
a 82 0.52 (0.50, 3.08) 82 1.05 (0.48, 4.0)
LBQ657
AUC0–24 h, h*ng/mL 81 122000 (19700) 16.2 82 364000 (62300) 17.1
AUClast, h*ng/mL 82 121000 (22200) 18.3 82 364000 (62400) 17.1
Cmax, ng/mL 82 13700 (2490) 18.2 82 40700 (6990) 17.2
Tmax, h
a 82 2.07 (1.05, 5.07) 82 3.05 (2.05, 5.07)
Valsartan
AUC0–24 h, h*ng/mL 81 30500 (14500) 47.5 82 66000 (25400) 38.5
AUClast, h*ng/mL 82 30300 (14500) 47.9 82 66000 (25400) 38.5
Cmax, ng/mL 82 4690 (2210) 47.2 82 9360 (3790) 40.5
Tmax, h
a 82 2.07 (1.05, 5.07) 82 2.07 (1.03, 4.07)
AUC0–24 h area under the plasma concentration-time curve from 0 to 24 h post-dose, AUClast AUC up to the last
measured concentration,Cmax peak plasma drug concentration,CV coefficient of variance, SD standard deviation,
Tmax time to reach Cmax
a Data are presented as median (range)
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predispose them and contribute to potentially life-threatening
cardiac arrhythmias, including autonomic imbalance, electro-
lyte abnormalities, and QT-prolonging co-treatments. They
are also at significantly increased risk for malignant ventricu-
lar death and sudden death [14].
LCZ696 is a novel drug approved for the treatment of
HFrEF. According to ICH E14 guidelines, a thorough assess-
ment of its effects on cardiac repolarization is required.
Whereas the autonomic and neurohormonal milieu present
in patients with HF differs substantially from healthy subjects,
the TQT study environment provides the optimally standard-
ized environment required to identify modest underlying
changes in cardiac repolarization, and studies in healthy sub-
jects are generally considered acceptable to inform drug-
related repolarization liability [12].
This study evaluated the effect of LCZ696 400 mg,
representing the total daily dose of the highest approved clinical
dose and regimen (200 mg twice daily), and 1200 mg,
representing a 6-fold multitude of any given single dose and
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concentrations observed in the present QTc study exceeded
observed steady-state plasma concentration in healthy subjects
and patients with heart failure. Furthermore, all LCZ696 analytes
have a short half-life, high-plasma protein binding andwere fully
characterized regarding their effect on the QTc interval, thereby
justifying a single-dose study design and the selected doses.
The results indicate no relevant impact on cardiac repolar-
ization with LCZ696 at either doses as evidenced by a mean
ΔΔQTcF <5mswith an upper bound <10ms, in contrast to the
positive comparator, moxifloxacin. LCZ696 administration in
healthy subjects was associated with transient asymptomatic
increase in HR. Changes in HR have the potential to impact
the performance of rate-corrected QT values. Published liter-
ature indicates that the Fridericia formula performs better un-
der conditions of alterations in HR, particularly when it is
decreased; therefore, a formal adequacy assessment was per-
formed to confirm the superior QT correction method for the
study population [4, 15, 16].
The lack of a relevant effect of LCZ696 on cardiac repo-
larization is evidenced both by the absence of a relevant mean
change in ΔΔQTcF, and the absence of outlier values during
categorical change analyses. In addition, central tendency and
categorical analyses of the prespecified ECG-derived PR in-
terval and QRS duration did not show any clinically relevant
treatment-related changes. The increased mean HR observed
at 8 h following treatment with LCZ696 400 and 1200 mg
compared with placebo or moxifloxacin was not dose related
and was not temporally related to the maximum drug expo-
sure. It may possibly be related to activity, as the earlier HR
measurements on the assessment days were made during bed
rest, while later measurements such as at 8 h post-dose were
collected while the subjects were ambulant.
The PK analyses of LCZ696 revealed a dose proportional
increase in the exposure of LBQ657 (the active metabolite of
sacubitril), whereas the increase in the valsartan exposure was
less than dose proportional, similar to the observations report-
ed by Gu J et al. [3]. The observed mean Cmax for all three
LCZ696 analytes (sacubitril, 7780 ng/mL; LBQ657,
40700 ng/mL; and valsartan, 9360 ng/mL) following the ad-
ministration of a supratherapeutic dose of LCZ696 (1200 mg)
in this study exceeded the highest exposures of LCZ696
analytes observed to date at steady state in subjects with se-
vere renal impairment receiving LCZ696 400 mg once daily
for 5 days (sacubitril, 4960 ng/mL; LBQ657, 30650 ng/mL;
and valsartan, 5852 ng/mL) [17]. The mean maximum QTcF
was noted at 1 h post-dose for both 400 and 1200 mg dose
levels, similar to the median Tmax for sacubitril of 30 min for
the 400 mg dose and 1 h for the 1200 mg dose. In contrast, the
Tmax for LBQ657 and valsartan occurred at 2–3 h post-dose.
The upper bound of the two-sided 90 % CI of the model-
predicted regression lines for the relationship between ΔΔQTcF
and concentration of LCZ696 analytes at the supratherapeutic
dose were below 10 ms, except for sacubitril, at concentrations
>15000 ng/mL. However, the observed mean ΔΔQTcF values,
corresponding to sacubitril concentrations >15000 ng/mL,
remained below 10 ms. Sacubitril concentrations are not ex-
pected to exceed 15000 ng/mL upon the administration of
single or multiple doses of LCZ696 400mg (therapeutic dose).
Even in subjects with severe renal impairment, the mean peak
plasma concentration of sacubitril after multiple doses of
LCZ696 400 mg once daily for 5 days was 4960 ng/mL [17],
3-fold lower than the highest individual Cmax of sacubitril fol-
lowing LCZ696 1200 mg administration in this study.
Therefore, the model-predicted values for high exposures to
sacubitril are not considered to be of clinical relevance.
LCZ696 (400 mg and 1200 mg) and moxifloxacin
(400 mg) single doses were generally safe and well tolerated.
The overall safety profile in this study in healthy subjects
was similar to the known safety profile of LCZ696 [18–20].
There were no repolarization changes on the ECGs and no AE
reports that could suggest a potential for a pro-arrhythmic
effect of LCZ696.
The major limitation of the present study is that the infor-
mation was collected in healthy subjects and not in patients
with HF, and that the supratherapeutic dose provides modest
safety margins of 2.4-fold, 2.9-fold, and 2.0-fold, respectively,
for the Cmax of sacubitril, LBQ657, and valsartan compared
with patients with severe renal impairment.
Conclusions
Single therapeutic and supratherapeutic oral doses of LCZ696
(400 and 1200 mg) did not affect cardiac repolarization, as
evidenced by the lack of effect on QTc interval.
Moxifloxacin was associated with the expected prolongation
of the QT interval, thereby demonstrating assay sensitivity.
LCZ696 at 400 and 1200 mg doses was generally safe and
well tolerated in this study.
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